Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board

Research output: Contribution to journalArticle

Abstract

Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalTrends in Immunology
Volume40
Issue number2
DOIs
Publication statusPublished - Feb 2019

Fingerprint

Anti-Idiotypic Antibodies
NK Cell Lectin-Like Receptor Subfamily C
T-Lymphocytes
Neoplasms
Cell Proliferation
Antibodies
Therapeutics

Cite this

Immune Checkpoint Inhibitors : Anti-NKG2A Antibodies on Board. / Mingari, Maria Cristina; Pietra, Gabriella; Moretta, Lorenzo.

In: Trends in Immunology, Vol. 40, No. 2, 02.2019, p. 83-85.

Research output: Contribution to journalArticle

@article{4363b69a411b4026a68bd137d2dab6c1,
title = "Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board",
abstract = "Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.",
author = "Mingari, {Maria Cristina} and Gabriella Pietra and Lorenzo Moretta",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "2",
doi = "10.1016/j.it.2018.12.009",
language = "English",
volume = "40",
pages = "83--85",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitors

T2 - Anti-NKG2A Antibodies on Board

AU - Mingari, Maria Cristina

AU - Pietra, Gabriella

AU - Moretta, Lorenzo

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

AB - Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

U2 - 10.1016/j.it.2018.12.009

DO - 10.1016/j.it.2018.12.009

M3 - Article

C2 - 30609967

VL - 40

SP - 83

EP - 85

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 2

ER -